文献速递间质性肺疾病

特发性肺纤维化临床试验终点:聚焦「感受、功能、生存」的多方共识

Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency.
PubMed 文献 · Am J Respir Crit Care Med · 2024-01-01

2023年6月一场标志性研讨会汇集43名美国及国际参与者,包括IPF患者、研究者和监管代表,讨论IPF临床试验终点的未来方向。会议按FDA「感受、功能、生存」标准评估终点,形成三大主题:共识采用反映患者真实体验的终点;考虑用复合终点替代FVC作为主要终点;支持简化易用的患者报告结局作为主要复合终点组分或关键次要终点。

要点

  • IPF试验终点应锚定患者真实体验:感受、功能、生存。
  • 可考虑以含「感受、功能、生存」 measures或FVC组分的复合终点替代FVC主要终点。
  • 简化易用的PRO可作为主要复合终点组分或关键次要终点。

核心结论

  • 未来IPF临床试验设计可能迎来转折点,更贴合对患者有意义的结果。
  • 多学科利益相关者达成集体共识:IPF试验终点应锚定患者真实体验,即感受、功能与生存。

研究设计与样本

  • 2023年6月召开标志性线下研讨会,汇集来自美国及国际的43名参与者。
  • 参与者包括IPF患者、研究者与监管代表,患者倡导者深度参与讨论。
  • 按监管标准及FDA「感受、功能、生存」标准评估终点。

主要发现

  • 形成三大主题:共识采用反映IPF患者真实体验的终点。
  • 考虑替换FVC作为主要终点,可能采用含「感受、功能、生存」测量或FVC组分的复合终点。
  • 支持简化易用的患者报告结局作为主要复合终点组分或关键次要终点,功能测试作为次要终点,新生物标志物作为支持性措施。

关键数值与推荐

  • FDA「感受、功能、生存」标准用于评估终点。
  • FDA《Multiple Endpoints in Clinical Trials》行业指南作为参考文件。

临床怎么用

  • 在IPF临床试验设计中优先采用反映患者感受、功能与生存的终点。
  • 可探索以复合终点替代FVC作为主要终点。
  • 将简化PRO纳入主要复合终点或关键次要终点,功能测试作为次要终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Idiopathic pulmonary fibrosis (IPF) carries significant mortality and unpredictable progression, with limited therapeutic options. Designing trials with patient-meaningful endpoints, enhancing the reliability and interpretability of results, and streamlining the regulatory approval process are of critical importance to advancing clinical care in IPF. Methods: A landmark in-person symposium in June 2023 assembled 43 participants from the US and internationally, including patients with IPF, investigators, and regulatory representatives, to discuss the immediate future of IPF clinical trial endpoints. Patient advocates were central to discussions, which evaluated endpoints according to regulatory standards and the FDA's 'feels, functions, survives' criteria. Results: Three themes emerged: 1) consensus on endpoints mirroring the lived experiences of patients with IPF; 2) consideration of replacing forced vital capacity (FVC) as the primary endpoint, potentially by composite endpoints that include 'feels, functions, survives' measures or FVC as components; 3) support for simplified, user-friendly patient-reported outcomes (PROs) as either components of primary composite endpoints or key secondary endpoints, supplemented by functional tests as secondary endpoints and novel biomarkers as supportive measures (FDA Guidance for Industry (Multiple Endpoints in Clinical Trials) available at: https://www.fda.gov/media/162416/download). Conclusions: This report, detailing the proceedings of this pivotal symposium, suggests a potential turning point in designing future IPF clinical trials more attuned to outcomes meaningful to patients, and documents the collective agreement across multidisciplinary stakeholders on the importance of anchoring IPF trial endpoints on real patient experiences-namely, how they feel, function, and survive. There is considerable optimism that clinical care in IPF will progress through trials focused on patient-centric insights, ultimately guiding transformative treatment strategies to enhance patients' quality of life and survival.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Raghu G, Ghazipura M, Fleming TR, et al. Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency. Am J Respir Crit Care Med. 2024. PMID: 38174955. doi:10.1164/rccm.202312-2213SO

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。